Fertility Challenges and Solutions in Women with Cancer by Hatem A. Azim & Isabelle Demeestere & Fedro A. Peccatori

Author:Hatem A. Azim & Isabelle Demeestere & Fedro A. Peccatori
Language: eng
Format: epub
ISBN: 9783030240868
Publisher: Springer International Publishing

Rituximab

Rituximab is a monoclonal antibody targeting the CD20 antigen approved for the treatment of chronic lymphocytic leukemia in combination with fludarabine and cyclophosphamide or chlorambucil as well as for other hematologic malignancies [76, 77]. The addition of rituximab to chemotherapy does not increase the risk of impaired ovarian function, especially in women younger than 40 years old [78].

BRAF Inhibitors and MEK Inhibitors

Approximately 50% of melanomas harbor activating BRAF mutations. BRAF is a member of the RAF kinase family, acting in the ERK/MAP kinase pathway that regulates cell proliferation, differentiation, and survival [79]. FDA has recently approved the combination of dabrafenib (BRAF inhibitor) and trametinib (MEK inhibitor) for the adjuvant treatment of patients with BRAF-positive stage III melanoma [80]. This combination demonstrated to reduce the risk of death by 53% compared with placebo in patients with BRAF-mutated stage III melanoma; however, little is known about their impact on the fertility of treated younger women. As a result, before treatment initiation, fertility preservation options should be discussed with patients that have indication to start such regimen and wishing to complete their family plans [81].

Download

Copyright Disclaimer:
This site does not store any files on its server. We only index and link to content provided by other sites. Please contact the content providers to delete copyright contents if any and email us, we'll remove relevant links or contents immediately.